Skip to main content

Table 2 Comparison of clinical characteristics between patients with and without postoperative complications

From: The impact of preoperative immunonutritional status on postoperative complications in ovarian cancer

 

No postoperative complications (N = 357)

Postoperative complications (N = 565)

P value

Age at diagnosis (years), median (IQR)

52 (46, 58)

53 (47, 60)

0.060

NLR

  

< 0.001

   ≤ 2.46

177 (49.6)

187 (33.1)

 

   > 2.46

180 (50.4)

378 (66.9)

 

PLR

  

< 0.001

   ≤ 227.52

268 (75.1)

320 (56.6)

 

   > 227.52

89 (24.9)

245 (43.4)

 

LMR

  

< 0.001

   ≤ 3.70

170 (47.6)

387 (68.5)

 

   > 3.70

187 (52.4)

178 (31.5)

 

TCLR

  

0.001

   ≤ 3.39

250 (70.0)

338 (59.8)

 

   > 3.39

107 (30.0)

227 (40.2)

 

FLR

  

< 0.001

   ≤ 2.64

208 (58.3)

217 (38.4)

 

   > 2.64

149 (41.7)

348 (61.6)

 

FAR

  

< 0.001

   ≤ 10.77

258 (72.3)

278 (49.2)

 

   > 10.77

99 (27.7)

287 (50.8)

 

SII

  

< 0.001

   ≤ 818.23

228 (63.9)

260 (46.0)

 

   > 818.23

129 (36.1)

305 (54.0)

 

PNI

  

< 0.001

   ≤ 46.73

112 (31.4)

348 (61.6)

 

   > 46.73

245 (68.6)

217 (38.4)

 

CONUT

  

< 0.001

   ≤ 4

308 (86.3)

384 (68.0)

 

   > 4

49 (13.7)

181 (32.0)

 

RBC (10^12/L)

  

< 0.001

   < 3.5

11 (3.1)

64 (11.3)

 

   ≥ 3.5

346 (96.9)

501 (88.7)

 

Hemoglobin (g/L)

  

< 0.001

   < 120

136 (38.1)

310 (54.9)

 

   ≥ 120

221 (61.9)

255 (45.1)

 

CA125 (U/mL)

357.8 (116.7, 1000.0)

680.0 (240.4, 1703.6)

< 0.001

BMI (kg/m2)

22.3 (20.6, 24.3)

21.9 (20.0, 23.8)

0.438

Histology

  

0.096

   High-grade serous carcinoma

214 (59.9)

383 (67.8)

 

   Low-grade serous carcinoma

9 (2.5)

19 (3.4)

 

   Endometrioid carcinoma

36 (10.1)

37 (6.5)

 

   Mucinous carcinoma

36 (10.1)

45 (8.0)

 

   Ovarian clear cell carcinoma

32 (9.0)

48 (8.5)

 

   Others

30 (8.4)

33 (5.8)

 

FIGO stage

  

< 0.001

   I

99 (27.7)

92 (16.3)

 

   II

61 (17.1)

71 (12.6)

 

   III

177 (49.6)

341 (60.4)

 

   IV

20 (5.6)

61 (10.8)

 

Tumor laterality

  

0.073

   Unilateral

168 (47.1)

237 (41.9)

 

   Bilateral

189 (52.9)

328 (58.1)

 

Ascites

  

< 0.001

   No

136 (38.1)

118 (20.9)

 

   Yes

221 (61.9)

447 (79.1)

 

Hydrothorax

  

< 0.001

   No

338 (94.7)

469 (83.0)

 

   Yes

19 (5.3)

96 (17.0)

 

Menopause

  

0.395

   No

155 (43.4)

239 (42.3)

 

   Yes

202 (56.6)

326 (57.7)

 

Comorbidities

  

0.316

   No

297 (83.2)

478 (84.6)

 

   Yes

60 (16.8)

87 (15.4)

 

Family history of cancer

  

0.329

   No

303 (84.9)

472 (83.5)

 

   Yes

54 (15.1)

93 (16.5)

 

Surgery methods

  

< 0.001

   Laparotomy

249 (69.7)

472 (83.5)

 

   Laparoscopy

108 (30.3)

93 (16.5)

 

Surgery procedure

   

   Upper abdominal surgery

7 (2.0)

28 (5.0)

0.014

   Enterectomy

28 (7.8)

106 (18.8)

< 0.001

   Lymphadenectomy

270 (75.6)

416 (73.6)

0.275

Lymph node metastasis

  

0.004

   Negative

194 (71.9)

249 (59.9)

 

   Positive

76 (28.1)

167 (40.1)

 

Residue disease

  

0.003

   No residual disease

210 (58.8)

268 (47.4)

 

   ≤ 1 cm

91 (25.5)

181 (32.0)

 

   > 1 cm

56 (15.7)

116 (20.5)

 

Postoperative hospitalization (days), median (IQR)

14 (8,14)

13 (10,17)

< 0.001

Postoperative chemotherapy

  

0.298

   No

29 (8.1)

53 (9.4)

 

   Yes

328 (91.9)

512 (90.6)

 

Chemotherapy cycle

  

0.395

   < 6

155 (43.4)

239 (42.3)

 

   ≥ 6

202 (56.6)

326 (57.7)

 

PARP inhibitors

  

0.718

   No

353 (98.9)

561 (99.3)

 

   Yes

4 (1.1)

4 (0.7)

 

Bevacizumab

  

1.000

   No

356 (99.6)

563 (99.7)

 

   Yes

1 (0.4)

2 (0.3)

 

Recurrence status

  

< 0.001

   No

202 (56.6)

250 (44.2)

 

   Yes

155 (43.4)

315 (55.8)

 

PFS (months, 95% CI)a

69.8 (45.8, 93.8)

37.6 (31.6, 43.6)

< 0.001

Survival status

  

< 0.001

   Alive

249 (69.7)

330 (58.4)

 

   Death

108 (30.3)

235 (41.6)

 

OS (months, 95% CI)a

85.7 (79.6, 91.8)

69.7 (60.9, 78.6)

0.001

  1. a. The median PFS or OS and 95% CI were calculated by the K-M survival curve BMI, Body mass index; CA125, Carbohydrate antigen 125; CONUT, Controlling nutritional status score; FAR, Fibrinogen to albumin ratio; FIGO, International Federation of Gynecology and Obstetrics; FLR, Fibrinogen to lymphocyte ratio; IQR, Interquartile range; LMR, Lymphocyte to monocyte ratio; NLR, Neutrophil to lymphocyte ratio; OS, Overall survival; PFS, Progression-free survival; PLR, Platelet to lymphocyte ratio; PNI, Prognostic nutritional index; RBC, Red blood cell count; SII, Systemic immune-inflammation index; TCLR, Total cholesterol to lymphocyte ratio
Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us